Celgene Corporation (NASDAQ:CELG) provided a business update as well as its preliminary 2014 results and financial outlook for 2015 and beyond at the 33rd Annual J.P. Morgan Healthcare Conference. In 2015, total net product sales are expected to be approximately $9,000 million to $9,500 million, a 22 percent increase year-over-year, based on the mid-point of the range. The negative impact of foreign exchange on net product sales is expected to approach $100 million in 2015 compared to 2014. For the full-year 2015, REVLIMID® net sales are expected to be in the range of $5,600 million to $5,700 million.
Help employers find you! Check out all the jobs and post your resume.
